Hidden lymphatic disease appears common in Noonan syndrome
Lymphatic involvement in Noonan syndrome is not confined to patients with obvious swelling. A cross-sectional study found central lymphatic abnormalities in individuals with the syndrome even when peripheral lymphedema was absent, expanding the clinical picture beyond what can be seen at the bedside.
The work compared 10 people with Noonan syndrome, including four with peripheral lymphedema and six without, against 10 age- and sex-matched cardiovascularly healthy controls. Central lymphatic anatomy was assessed with non-contrast T2-weighted MR-lymphangiography, while peripheral lymphatic morphology and function were evaluated using near-infrared fluorescence imaging and strain gauge plethysmography. The design matters because the lymphatic system can fail quietly for a long time before swelling becomes apparent, and imaging can capture that earlier phase.
Thoracic duct abnormalities were common. Variations in thoracic duct morphology appeared in 89% of the Noonan syndrome group, 8 of 9 individuals with evaluable imaging, compared with 20% of controls. Thoracic lymphatic classifications also differed significantly between the Noonan syndrome group and healthy controls, including in participants with and without lymphedema. In practical terms, the central lymphatic network was already atypical in many patients before overt limb swelling declared itself.
One sentence captures the central message: lymphatic disease in Noonan syndrome can be present before symptoms become obvious.
Central abnormalities were present even without lymphedema
Five of nine individuals with Noonan syndrome demonstrated central lymphatic abnormalities, and three of those five had no clinical signs of lymphatic disease. That finding pushes the phenotype upstream from the swollen leg or arm to the deeper thoracic drainage pathways that normally keep interstitial fluid moving in an orderly circuit. In a disorder rooted in developmental signaling, the lymphatic system may be structurally altered from the start, long before the patient develops visible edema.
This has direct diagnostic consequences. When lymphatic abnormalities exist in asymptomatic individuals, waiting for swelling to appear risks missing an important window for characterization and monitoring. The study suggests that central imaging may identify a latent disease burden that routine physical examination cannot detect. For clinicians caring for people with Noonan syndrome, a normal external exam does not exclude lymphatic pathology.
The finding also helps explain why lymphedema can appear inconsistently across patients with the same syndrome. Central transport defects may be present in a broader subset of patients, while the peripheral manifestation emerges only when the system can no longer compensate.
Peripheral flow defects tracked with clinically manifest swelling
Peripheral lymphatic function told a more selective story. Abnormal conduction in collecting vessels, defined by retrograde or absent flow, was detected in all four Noonan syndrome individuals with lymphedema. By contrast, peripheral conduction remained normal in asymptomatic Noonan syndrome participants and in controls. The separation between central and peripheral findings suggests a staged process rather than a single uniform defect.
In this cohort, central abnormalities appeared earlier, while abnormal peripheral conduction developed later in association with clinically evident lymphedema. That sequence is biologically plausible. The central lymphatic system acts as the high-capacity transport backbone; if that backbone is malformed, downstream collecting vessels may eventually be forced into maladaptive patterns, including reversed or absent flow. Once peripheral propulsion fails, fluid accumulates and swelling becomes visible.
The study therefore points to two related but not identical problems: congenital structural abnormalities in the central lymphatic network, and later functional failure in peripheral conducting vessels among those who actually develop lymphedema.
Imaging may redefine what counts as lymphatic involvement
The use of MR-lymphangiography, near-infrared fluorescence imaging, and strain gauge plethysmography gives the findings clinical texture. Each modality interrogates a different layer of the lymphatic system. MR-lymphangiography maps central anatomy without contrast, near-infrared fluorescence captures peripheral vessel behavior, and plethysmography adds a functional readout. Together, they reveal a disease process that physical examination alone would miss or underestimate.
That multi-modality approach is especially relevant in Noonan syndrome, where the phenotype is already broad and variable. A patient without limb swelling may still harbor thoracic duct irregularity or another central conducting defect. Detecting those changes could matter for surveillance, for planning procedures, and for understanding which patients are likely to progress to overt edema.
The authors framed the results as evidence that central lymphatic abnormalities extend beyond clinically apparent disease. Clinically, that means the threshold for suspicion should be lower than the threshold for visible swelling. In a syndrome already known for cardiovascular and developmental complications, lymphatic imaging may belong earlier in the diagnostic conversation than it often does now.
What this means for patients and clinicians
For families and clinicians, the most immediate implication is that lymphatic disease in Noonan syndrome may be underrecognized. A patient who has not developed lymphedema can still have demonstrable central lymphatic abnormalities. A patient with swelling may have progressed beyond that earlier stage into a pattern of peripheral conduction failure.
That distinction can shape monitoring. Individuals with Noonan syndrome and no current lymphedema may still warrant consideration of lymphatic imaging if symptoms, procedural planning, or broader clinical assessment raise concern. For those who already have swelling, imaging can help define whether disease is primarily central, peripheral, or both.
The study is small, and the sample size limits how far the findings can be generalized. Even so, the pattern is internally coherent: central abnormalities are frequent, peripheral abnormalities cluster with overt lymphedema, and asymptomatic individuals can already show hidden disease on imaging. The data broaden the recognized phenotype without overreaching beyond what was actually measured.
A larger unresolved question remains whether these imaging abnormalities can predict future lymphedema in those who are still asymptomatic. Another is whether serial lymphatic imaging could track progression or help refine follow-up intervals. For now, the study establishes a clear message from a small cohort: in Noonan syndrome, the lymphatic system can be abnormal long before the swelling is visible.